Impact funds help fight dementia and antibiotic resistance
Some of the world’s biggest health challenges do not lend themselves to conventional investment
To solve our greatest social and environmental challenges, we need to make more capital impact capital, and more stakeholders impact stakeholders. We teamed up with Financial Times to show that all investors can be impact investors.
FT’s special report looks at funds that put social pay-offs first — from greener energy in Nigeria to new jobs in the UK. Plus: pharma’s funding gap, biodiversity credits, and faith-based finance.
Marc Gitzinger started his “adventure” in antibiotics 12 years ago, co-founding Swiss start-up BioVersys to tackle deadly and drug-resistant pathogens, such as strains of tuberculosis. He has watched as even promising peer companies collapsed, and had to slow his own development programmes for fear of running out of money.
“I personally find it unacceptable that we would have drugs in hand that help a significant number of patients from not passing away — and we have to drop this for financial reasons, rather than scientific ones,” he says.